Literature DB >> 33183215

A Novel Cell-based In vitro Assay for Antiviral Activity of Interferons α, β, and γ by qPCR of MxA Gene Expression.

Mohamed A Saber1, Hend Okasha1, Fatma Khorshed1, Safia Samir1.   

Abstract

BACKGROUND: Human MxA gene is related to the class of interferon (IFN)-stimulated genes (ISGs) that plays a role in antiviral resistance.
OBJECTIVE: Implementation of standard curves obtained from designing a procedure for data processing in relative qPCR between MxA expression and interferon's antiviral activity (IU/ml). These standard curves can be used to detect the antiviral activity of any new compound rapidly and safely.
METHODS: To detect the optimum incubation time for maximum MxA gene expression in human peripheral blood mononuclear cells (PBMC), the isolated human PBMCs (1x106 cells) were incubated with a concentration of 1000 IU/ml of each IFN at different time intervals; 2 h, 4 h, 6 h, and 24 h post-treatment. A standard curve was performed for each IFN (α, β, and γ) at different concentrations (250, 500, 750, 1000, 1500, and 2000 IU/ml).
RESULTS: As observed at 4 h incubation time of 1000 IU/ml concentration, IFN-γ provided a higher expression of MxA compared to IFN-α and IFN-β. Correlation analyses between IFN-α and IFN-β, IFN-β and IFN-γ were non-significant. However, there was a significant correlation between IFN-α and IFN-γ (p<0.01). Receiver operator characteristic (ROC) analysis revealed that cut-off values of IFN- γ, IFN-β, and IFN-α were 58.14 > 7.31 and > 3.33, respectively.
CONCLUSIONS: The relative expression of MxA is a biomarker for IFN-α, β, and γ, especially IFN-α. It has compiled and validated a standard curve-based protocol for PCR data processing. It shows that the standard curve is an easy alternative tool to assess antiviral activity. We revised all patents relating to the antiviral assays of the used interferons. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  MxA; PBMCs; antiviral; interferon-alpha; interferon-beta; interferon-gamma; qRT-PCR

Mesh:

Substances:

Year:  2021        PMID: 33183215     DOI: 10.2174/1872208314666201112105053

Source DB:  PubMed          Journal:  Recent Pat Biotechnol        ISSN: 1872-2083


  3 in total

Review 1.  Emerging concepts of type I interferons in SLE pathogenesis and therapy.

Authors:  Antonios Psarras; Miriam Wittmann; Edward M Vital
Journal:  Nat Rev Rheumatol       Date:  2022-09-12       Impact factor: 32.286

2.  Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.

Authors:  Pablo Aliaga-Gaspar; Isaac Hurtado-Guerrero; Nicolas Lundahl Ciano-Petersen; Patricia Urbaneja; Isabel Brichette-Mieg; Virginia Reyes; Jose Luis Rodriguez-Bada; Roberto Alvarez-Lafuente; Rafael Arroyo; Ester Quintana; Lluis Ramió-Torrentà; Ana Alonso; Laura Leyva; Oscar Fernández; Begoña Oliver-Martos
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

3.  Possible internal viral shedding and interferon production after clinical recovery from COVID-19: Case report.

Authors:  Asuka Ito; Takayuki Okada; Naoki Minato; Fumiyuki Hattori
Journal:  Front Med (Lausanne)       Date:  2022-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.